Brokerages Anticipate Nabriva Therapeutics plc (NASDAQ:NBRV) Will Post Earnings of -$0.19 Per Share

Wall Street analysts expect that Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) will announce ($0.19) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Nabriva Therapeutics’ earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.20). Nabriva Therapeutics reported earnings per share of ($0.53) during the same quarter last year, which would indicate a positive year over year growth rate of 64.2%. The company is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Nabriva Therapeutics will report full-year earnings of ($0.67) per share for the current fiscal year, with EPS estimates ranging from ($0.73) to ($0.61). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.34) per share, with EPS estimates ranging from ($0.35) to ($0.33). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Nabriva Therapeutics.

Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) last announced its quarterly earnings data on Tuesday, March 29th. The biotechnology company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.05). Nabriva Therapeutics had a negative return on equity of 82.13% and a negative net margin of 171.14%. During the same period in the previous year, the company posted ($1.11) EPS.

Several equities research analysts recently issued reports on NBRV shares. Northland Securities cut their price objective on Nabriva Therapeutics from $4.00 to $2.00 and set an “outperform” rating on the stock in a report on Wednesday, March 30th. Zacks Investment Research cut Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 5th. Finally, StockNews.com began coverage on Nabriva Therapeutics in a research report on Monday, April 4th. They set a “hold” rating for the company.

Several hedge funds have recently modified their holdings of NBRV. Advisor Group Holdings Inc. grew its holdings in shares of Nabriva Therapeutics by 5,200.0% in the 3rd quarter. Advisor Group Holdings Inc. now owns 26,500 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 26,000 shares during the period. Millennium Management LLC purchased a new stake in shares of Nabriva Therapeutics during the 2nd quarter valued at about $42,000. Two Sigma Securities LLC purchased a new stake in Nabriva Therapeutics during the 3rd quarter worth approximately $48,000. Geode Capital Management LLC grew its position in shares of Nabriva Therapeutics by 102.9% in the 3rd quarter. Geode Capital Management LLC now owns 42,738 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 21,672 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its position in shares of Nabriva Therapeutics by 144.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 41,079 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 24,300 shares in the last quarter. 1.36% of the stock is owned by institutional investors and hedge funds.

NASDAQ:NBRV traded down $0.01 on Monday, reaching $0.38. The company’s stock had a trading volume of 343,169 shares, compared to its average volume of 436,921. Nabriva Therapeutics has a 12-month low of $0.37 and a 12-month high of $2.32. The company has a quick ratio of 2.94, a current ratio of 3.59 and a debt-to-equity ratio of 0.08. The firm has a market cap of $204.77 million, a price-to-earnings ratio of -0.30 and a beta of 1.55. The stock has a 50 day moving average price of $0.46 and a 200 day moving average price of $0.72.

Nabriva Therapeutics Company Profile (Get Rating)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.

Featured Stories